Synlogic is delivering the power of synthetic biology to medicine, combining the precision of engineering with rational drug development. With a premiere synthetic biology drug discovery engine that leverages a reproducible, modular approach to microbial engineering, we design Synthetic Biotics to treat disease in new ways.

Synthetic biology brings engineering principles to science and enable the design of entirely new biological systems, genetic circuits and molecular components that can be used to create medicines that can have a meaningful impact for patients.

The Path to Possibilities

Starting in the 1960s, advancements in the scientific understanding of how molecular networks regulate cellular function and how gene expression is regulated within cells laid the foundation for synthetic biology. Further catalyzed by advances in molecular biology tools and DNA sequencing, these findings led to a new era in biology where genetic toggles, feedback circuits, and other tools made it possible to “program” bacterial cells in much the same way we program computers to perform different functions.

With the completion of the landmark Human Genome Project in 2003, scientists had access to new insights about the genetic causes of disease. The 2000s were also the first-time bacteria were successfully reprogrammed to carry out specific functions, including attacking cancer cells and producing biofuel.

Synlogic was founded in 2014 as the first synthetic biology company entirely focused on development of new therapeutics based on the principles of synthetic biology, leading to a new therapeutic modality known as Synthetic Biotics.

Driving Progress for Patients

Unlocking the potential of Synthetic Biotic medicine to treat different diseases begins with biology. From metabolic diseases where we design bacteria to play a precise therapeutic role in the gastro-intestinal (GI) tract to immunomodulation where our novel science and approach is built on advances in the understanding of the interaction between bacteria and the immune system, Synlogic is using established techniques and principles in synthetic biology as a technology to design medicines.

The Synlogic Approach: Designing Synthetic Biotics

Synlogic is pioneering the development and use of Synthetic Biotics in medicine. Our platform combines deep synthetic biology expertise with an innovative manufacturing approach and translational ingenuity to build a pipeline of first-in-class biotherapeutics based on precision genetic engineering of well-characterized probiotics to deliver therapeutic benefit. We begin with an advanced understanding of molecular biology, microbial engineering and disease physiology. From there, our proprietary library of innovative tools and modular components includes state-of-the art metabolic gene circuitry and regulatory genetic switches that activate the medicine in its intended environment. Our platform rapidly produces bacterial microbes designed to perform specific therapeutic functions.

Synlogic is delivering the power of synthetic biology to medicine, combining the precision of engineering with rational drug development. With a premiere synthetic biology platform that leverages a reproducible, modular approach to microbial engineering, we design Synthetic Biotic medicines to treat disease in new ways.

Synthetic biology brings engineering principles to science enabling the design of new biological systems, genetic circuits and molecular components that can be used to improve the world around us and create medicines that can have a meaningful impact for patients.

The Path to Possibilities

Starting in the 1960s, key advancements in the scientific understanding of how molecular networks regulate cellular function, and how gene expression is regulated within cells, laid the foundation for synthetic biology. Further catalyzed by advances in molecular biology tools and DNA sequencing, a new era in biology was born: an era in which genetic toggles, feedback circuits, and other tools enabled the programming of bacterial cells analogous to the programming of a computer.

With the completion of the landmark Human Genome Project in 2003, scientists were able to understand the genetic basis behind disease in new ways. The 2000s were also the first time bacteria were successfully reprogrammed to carry out specific functions, including attacking cancer cells and producing biofuel. In the last decade, synthetic biology has taken flight.

Synlogic was founded in 2014 as the first synthetic biology company entirely focused on therapeutics – a new therapeutic modality known as Synthetic Biotic medicines.

Driving Progress for Patients

Biology defines the path we are on – providing important indicators that reveal the potential of Synthetic Biotic medicine across diseases. From metabolic diseases where we design bacteria to play a precise therapeutic role in the gastro-intestinal (GI) tract to immunomodulation where our novel science and approach is built on advances in the understanding of the interaction between bacteria and the immune system, we use synthetic biology as a technology to design medicines that will change lives.

The Synlogic Approach: Designing SYNTHETIC BIOTIC Medicines

Synlogic is pioneering the development and use of Synthetic Biotics in medicine. Our Synthetic Biotic platform combines deep synthetic biology expertise with an innovative manufacturing approach and translational ingenuity to build a pipeline of live bacterial, first-in-class Synthetic Biotic medicines. By bringing together molecular biology, microbial engineering and disease physiology with our proprietary library of innovative tools and modular components, such as state-of-the art metabolic gene circuitry and regulatory genetic switches that activate the medicine in its intended environment, we are able to produce bacterial microbes designed to perform specific therapeutic functions.

Metabolic Disease

Synlogic has extensively validated the ability of our genetically engineered probiotic medicines to safely and effectively deliver therapeutic benefit through non-systemic, GI-based interventions. As a result, our platform has the potential to deliver new approaches to treatment for many serious metabolic diseases, including:

Phenylketonuria or PKU

Patients living with PKU are not able to break down the phenylalanine amino acid (Phe) that is found in many foods, including vegetables, breads, and cereals. The buildup of Phe can cause severe neurological disorders and developmental delays. SYNB1618 and SYNB1934 are both oral drug candidates designed to consume Phe in the GI tract, with the goal of enabling those living with PKU to consume higher amounts of natural protein.

Homocystinuria (HCU)

Homocystinuria (HCU) is a rare metabolic disease that is caused by an inborn error of metabolism, specifically the loss of function of the enzyme cystathionine beta-synthase, which results in excessive accumulation of homocysteine and its metabolites in the blood and urine. People with HCU face risks of complications including thromboembolism, lens dislocation, skeletal abnormalities, developmental delay, and intellectual disability. Many patients are required to comply with a rigid methionine-restricted diet and currently approved treatment options for HCU are limited due to efficacy and tolerability. In November 2021, Synlogic announced SYNB1353, an orally-administered, non-systemically absorbed drug candidate. SYNB1353 was designed using genetic engineering to program the probiotic bacteria E. coli Nissle (EcN)to consume methionine within the gastrointestinal tract, thereby preventing methionine absorption and conversion to homocysteine in plasma. SYNB1353 is currently in IND-enabling studies and developed as part of a research collaboration with Synlogic and Gingko Bioworks.

Enteric Hyperoxaluria

Enteric hyperoxaluria is a chronic, progressive disease characterized by high levels of urinary oxalate, the leading cause of recurrent kidney stones. Oxalate crystals can damage kidneys, potentially leading to damage that can include nephrocalcinosis, chronic kidney disease (CKD) and end-stage renal disease (ESRD). Enteric hyperoxaluria often occurs as a result of a primary insult to the bowel, such as inflammatory bowel disease or short bowel syndrome, or as a result of surgical procedures such as Roux-en-Y bariatric weight-loss surgery. There are no approved treatment options. SYNB88802 is a drug candidate designed to consume dietary oxalate throughout the GI tract.

Immunomodulation

The immune system and bacteria are linked in intricate ways. Trillions of bacteria live on and around each one of us, interacting with our immune system. Bacteria have evolved and created mechanisms to control our immune response. Researchers at Synlogic are developing new strategies to harness the interactions between bacteria and the immune system using the tools of synthetic biology to genetically engineer medicines that cam modulate the immune response to fight cancer and auto-immune diseases.

Inflammatory Bowel Disease

Inflammatory bowel diseases (IBD) such as Crohn’s disease or ulcerative colitis result in chronic inflammation in the intestinal tract driven by an over activation of the immune system. These diseases can lead to severe health problems, resulting in debilitating abdominal pain and GI distress and often requiring invasive surgical interventions. Current therapies based on systemic immunosuppression fail to induce and maintain long-term remission in most patients. Synlogic is working to develop Synthetic Biotic medicines able to suppress the overactive immune response to improve the leakiness of the GI tract lining and reduce the signs and symptoms of IBD.